Puma Biotechnology Inc (NYSE:PBYI)‘s stock had its “buy” rating restated by equities researchers at Barclays PLC in a research report issued on Friday. They presently have a $122.00 target price on the biopharmaceutical company’s stock. Barclays PLC’s target price points to a potential upside of 14.29% from the company’s previous close.
Other research analysts also recently issued reports about the stock. Citigroup Inc. boosted their target price on shares of Puma Biotechnology from $156.00 to $164.00 and gave the company a “buy” rating in a research report on Friday. Royal Bank Of Canada decreased their target price on shares of Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating for the company in a research report on Friday. They noted that the move was a valuation call. J P Morgan Chase & Co set a $105.00 price objective on shares of Puma Biotechnology and gave the company a “buy” rating in a report on Wednesday, August 9th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $118.00 price objective (up previously from $105.00) on shares of Puma Biotechnology in a report on Tuesday, July 18th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of Puma Biotechnology in a report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Puma Biotechnology presently has a consensus rating of “Buy” and an average price target of $130.00.
Puma Biotechnology (NYSE PBYI) traded down $20.45 during midday trading on Friday, reaching $106.75. 2,420,403 shares of the company were exchanged, compared to its average volume of 1,094,703. Puma Biotechnology has a 52 week low of $28.35 and a 52 week high of $136.90.
Puma Biotechnology (NYSE:PBYI) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to analyst estimates of $3.78 million. During the same quarter in the prior year, the firm earned ($1.11) earnings per share.
“Puma Biotechnology Inc (PBYI) Stock Rating Reaffirmed by Barclays PLC” was first reported by GBand is of DT GB gearsofbiz If you are viewing this report on another site, United States and international and of this report at http://gearsofbiz.com/2017/11/10/puma-biotechnology-inc-pbyi-stock-rating-reaffirmed-by-barclays-plc
In other news, SVP Richard Paul Bryce sold 15,000 shares of the business’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the completion of the sale, the senior vice president now owns 42,239 shares of the company’s stock, valued at $5,068,680. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.70% of the stock is owned by insiders.
Several hedge funds have recently added to or reduced their stakes in PBYI. Parametric Portfolio Associates LLC purchased a new stake in shares of Puma Biotechnology during the first quarter worth about $257,000. Teachers Advisors LLC grew its stake in Puma Biotechnology by 2.0% during the 1st quarter. Teachers Advisors LLC now owns 145,197 shares of the biopharmaceutical company’s stock valued at $5,401,000 after acquiring an additional 2,824 shares in the last quarter. Legal & General Group Plc grew its stake in Puma Biotechnology by 2.8% during the 1st quarter. Legal & General Group Plc now owns 9,297 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 249 shares in the last quarter. Vanguard Group Inc. grew its stake in Puma Biotechnology by 4.4% during the 1st quarter. Vanguard Group Inc. now owns 2,428,909 shares of the biopharmaceutical company’s stock valued at $90,355,000 after acquiring an additional 101,722 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Puma Biotechnology by 17.3% during the 1st quarter. Geode Capital Management LLC now owns 232,371 shares of the biopharmaceutical company’s stock valued at $8,644,000 after acquiring an additional 34,190 shares in the last quarter. 80.98% of the stock is owned by institutional investors and hedge funds.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Puma Biotechnology Inc and related companies with MarketBeat.com’s FREE daily email newsletter.